简体中文
Chinese expert on blood diseases Huang Xiaojun unveiled his team's latest achievements in fighting the Aplastic anemia on Sunday.
Huang, head of the Institute of Hematology at the People's Hospital of Peking University, was invited to give special lecture entitled "Haploidentical Hematopoietic Stem Cell Transplantation for Severe Acquired Aplastic Anemia--Experience from China" at the annual meeting which was held in Osaka, western Japan from Friday to Sunday.
Huang presented the novel therapeutic strategies for severe aplastic anemia(SAA) and latest results of ongoing prospective mutil-center clinical trials in China.
Aplastic anemia is a disease in which the bone marrow, and the blood stem cells that reside there, are damaged. This causes a deficiency of all three blood cell types: red blood cells, white blood cells, and platelets.
The overall incidence of aplastic anemia is about 7.4/100,000 inhabitants per year in China and the incidence increased with age. The long-term survival of severe aplastic anemia(SAA) is only 10- 40 percent.
Medical therapy of aplastic anemia often includes suppression of immune-system and bone marrow transplantation(also called hematopoietic stem cell transplantation, the later one is considered the only potential curable therapy of SAA, as the multipotent stem cells in the bone marrow reconstitute all three blood cell lines, giving the patient a new immune system, red blood cells, and platelets. Human leukocyte antigenmatched sibling or unrelated donor used to be the only option of HSCT for SAA, however, due to the "One Child Policy" there had been a shortage of donors for Chinese SAA patients who need HSCT, Huang said.
Huang said his group developed a novel approach for HLA- mismatched/haploidentical hematopoietic stem cell transplantation for SAA (Transplantation from parents to children or inverse ), the rate of engraftment was 100 percent and long-term survival was about 76-90 percent. This novel strategies had been disseminated to the main HSCT centers around China, and one prospective mutil- center clinical trials had been carried out to evaluate the effectiveness and safety of this protocol.
It is believed that the encouraging results of Huang's team had great global influence: in the latest edition of Asia-Pacific guidelines for SAA, Haplo-HSCT had been promoted to second-line choice, which was the most important strategies alternative to HSCT from the HLA-matched siblings.
